These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 12006404

  • 1. Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe.
    Juhan-Vague I, Morange PE, Aubert H, Henry M, Aillaud MF, Alessi MC, Samnegård A, Hawe E, Yudkin J, Margaglione M, Di Minno G, Hamsten A, Humphries SE, HIFMECH Study Group.
    Arterioscler Thromb Vasc Biol; 2002 May 01; 22(5):867-73. PubMed ID: 12006404
    [Abstract] [Full Text] [Related]

  • 2. TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: the PRIME Study.
    Morange PE, Tregouet DA, Frere C, Luc G, Arveiler D, Ferrieres J, Amouyel P, Evans A, Ducimetiere P, Cambien F, Tiret L, Juhan-Vague I, Prime Study Group.
    J Thromb Haemost; 2005 Jul 01; 3(7):1503-10. PubMed ID: 15978108
    [Abstract] [Full Text] [Related]

  • 3. Association between TAFI antigen and Ala147Thr polymorphism of the TAFI gene and the angina pectoris incidence. The PRIME Study (Prospective Epidemiological Study of MI).
    Morange PE, Juhan-Vague I, Scarabin PY, Alessi MC, Luc G, Arveiler D, Ferrieres J, Amouyel P, Evans A, Ducimetiere P, PRIME Study group.
    Thromb Haemost; 2003 Mar 01; 89(3):554-60. PubMed ID: 12624641
    [Abstract] [Full Text] [Related]

  • 4. Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men.
    Meltzer ME, Doggen CJ, de Groot PG, Meijers JC, Rosendaal FR, Lisman T.
    Haematologica; 2009 Jun 01; 94(6):811-8. PubMed ID: 19377074
    [Abstract] [Full Text] [Related]

  • 5. Plasma thrombin-activatable fibrinolysis inhibitor levels and Thr325Ile polymorphism as a risk marker of myocardial infarction in Egyptian patients.
    Kamal HM, Ahmed AS, Fawzy MS, Mohamed FA, Elbaz AA.
    Acta Cardiol; 2011 Aug 01; 66(4):483-8. PubMed ID: 21894805
    [Abstract] [Full Text] [Related]

  • 6. Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system.
    Zorio E, Castelló R, Falcó C, España F, Osa A, Almenar L, Aznar J, Estellés A.
    Br J Haematol; 2003 Sep 01; 122(6):958-65. PubMed ID: 12956767
    [Abstract] [Full Text] [Related]

  • 7. Combined segregation-linkage analysis of plasma thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels with TAFI gene polymorphisms.
    Trégouet DA, Aubert H, Henry M, Morange P, Visvikis S, Juhan-Vague I, Tiret L.
    Hum Genet; 2001 Aug 01; 109(2):191-7. PubMed ID: 11511925
    [Abstract] [Full Text] [Related]

  • 8. [Prognosis value of thrombin activatable fibrinolysis inhibitor concentration and C1040T polymorphism in acute myocardial infarction treated with fibrinolysis].
    González FJ, Caturla JM, Fernández M, Carrasco R, Marco P, Sánchez J, Benlloch S.
    Med Intensiva; 2010 Nov 01; 34(8):513-22. PubMed ID: 20627371
    [Abstract] [Full Text] [Related]

  • 9. Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris.
    Brouwers GJ, Leebeek FW, Tanck MW, Wouter Jukema J, Kluft C, de Maat MP.
    Thromb Haemost; 2003 Jul 01; 90(1):92-100. PubMed ID: 12876631
    [Abstract] [Full Text] [Related]

  • 10. Identification of polymorphisms in the promoter and the 3' region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled.
    Henry M, Aubert H, Morange PE, Nanni I, Alessi MC, Tiret L, Juhan-Vague I.
    Blood; 2001 Apr 01; 97(7):2053-8. PubMed ID: 11264171
    [Abstract] [Full Text] [Related]

  • 11. Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to isoform-dependent artefact.
    Frère C, Morange PE, Saut N, Tregouet DA, Grosley M, Beltran J, Juhan-Vague I, Alessi MC.
    Thromb Haemost; 2005 Aug 01; 94(2):373-9. PubMed ID: 16113828
    [Abstract] [Full Text] [Related]

  • 12. Thrombin-activatable fibrinolysis inhibitor (TAFI) levels and its polymorphism rs3742264 are associated with dyslipidemia in a cohort of Brazilian subjects.
    Santos IR, Fernandes AP, Carvalho MG, Sousa MO, Ferreira CN, Gomes KB.
    Clin Chim Acta; 2014 Jun 10; 433():76-83. PubMed ID: 24631134
    [Abstract] [Full Text] [Related]

  • 13. High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke.
    Leebeek FW, Goor MP, Guimaraes AH, Brouwers GJ, Maat MP, Dippel DW, Rijken DC.
    J Thromb Haemost; 2005 Oct 10; 3(10):2211-8. PubMed ID: 16092924
    [Abstract] [Full Text] [Related]

  • 14. Plasma fibrinogen concentration predicts the risk of myocardial infarction differently in various parts of Europe: effects of beta-fibrinogen genotype and environmental factors. The HIFMECH Study.
    Mannila MN, Silveira A, Hawe E, Eriksson P, Aillaud MF, Juhan-Vague I, Yudkin J, Margaglione M, di Minno G, Mussoni L, Tremoli E, Humphries S, Hamsten A, HIFMECH Study Group.
    Thromb Haemost; 2004 Dec 10; 92(6):1240-9. PubMed ID: 15583729
    [Abstract] [Full Text] [Related]

  • 15. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
    Ermantas N, Guldiken S, Demir M, Tugrul A.
    Clin Appl Thromb Hemost; 2010 Oct 10; 16(5):568-73. PubMed ID: 19959491
    [Abstract] [Full Text] [Related]

  • 16. Thrombin activatable fibrinolysis inhibitor (TAFI): a molecular link between coagulation and fibrinolysis.
    Miljić P, Heylen E, Willemse J, Djordjević V, Radojković D, Colović M, Elezović I, Hendriks D.
    Srp Arh Celok Lek; 2010 Jan 10; 138 Suppl 1():74-8. PubMed ID: 20229688
    [Abstract] [Full Text] [Related]

  • 17. Plasma thrombin-activatable fibrinolysis inhibitor levels and its Thr325Ile polymorphism in breast cancer.
    Chengwei X, Xiaoli M, Yuan Z, Li P, Shengjiang W, Chao Y, Yunshan W.
    Blood Coagul Fibrinolysis; 2013 Oct 10; 24(7):698-703. PubMed ID: 23624357
    [Abstract] [Full Text] [Related]

  • 18. Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays.
    Guimarães AH, van Tilburg NH, Vos HL, Bertina RM, Rijken DC.
    Br J Haematol; 2004 Mar 10; 124(5):659-65. PubMed ID: 14871254
    [Abstract] [Full Text] [Related]

  • 19. [Study on the association of thrombin activatable fibrinolysis inhibitor and the Thr325Ile and Thr147Ala polymorphisms of its encoding gene CPB2 in patients with coronary heart disease].
    Xu CW, Wang LL, Wu XB, Zhao JJ, Du YM, Jiang CY.
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Aug 10; 25(4):438-42. PubMed ID: 18683146
    [Abstract] [Full Text] [Related]

  • 20. Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation.
    Antovic JP, Blombäck M.
    Thromb Res; 2002 Apr 01; 106(1):59-62. PubMed ID: 12165290
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.